Gene May Put Women With Migraine At Increased Risk Of Heart Disease And Stroke
Women who experience migraine with aura appear to be at an increased risk of heart disease and stroke if they have a certain gene, according to a study published in the July 30, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. For the study, researchers followed 25,001 Caucasian women for the occurrence of cardiovascular disease, including heart attacks and ischemic stroke.
Compliance To Proton Pump Inhibitors Reduces Costs
A new study reveals that patients with gastroesophageal reflux disease (GERD) who receive proton pump inhibitor (PPI) drugs require fewer health care services and incur lower costs if they conform to the recommended usage frequency.
Greater Risk Of Eating Disorder Symptoms Among Female Athletes And Exercisers
A recent study published by the International Journal of Eating Disorders reveals that university undergraduate women who actively participate in sports and exercise-related activities tend to have higher rates of attitudes and behaviors related to eating disorders compared to those who do not regularly exercise.
UPMC Conference To Discuss Newest Scientific Knowledge Forcing Doctors To Re-Think How To Safely Manage Concussions In Athletes Of All Levels
Treatment of concussions remains arguably the most complex and controversial issue in sports medicine for athletes of all ages, yet concussions occur in millions of athletes each year. The good news is that new scientific research continues to provide clearer knowledge for team doctors and athletic trainers, helping them to recognize and quantify the symptoms and effects of concussions.
Clinical Trial For The Treatment Of Inflammatory Bowel Disease Begins At Tel Aviv Sourasky Medical Center
Anadis Ltd (ASX:ANX; OTC:ANDIY), a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel.
The Link Between Gastric Reflux And Asthma
Researchers at Duke University Medical Center appear to have solved at least a piece of a puzzle that has mystified physicians for years: why so many patients with asthma also suffer from GERD, or gastroesophageal reflux disease. Clinicians first noted a relationship between the two diseases in the mid-1970s. Since then, studies have shown that anywhere from 50 to 90 percent of patients with asthma experience some aspect of GERD.
News Tips From The Journal Of Neuroscience
1. Hodgkin CHuxley Model of Backpropagating Spikes Yuguo Yu, Yousheng Shu, and David A. McCormick Axon potentials recorded in somata of pyramidal neurons in vivo have a fast rising phase and variable threshold, contrary to predictions of the Hodgkin¨CHuxley model. Some have suggested that this difference is due to cooperativity among sodium channels, resulting in many channels opening simultaneously. Yu et al.
Oxygen Therapy Might Ease Pain Of Migraine, Cluster Headaches
Two types of oxygen therapy could offer some relief to adults who suffer from disabling migraine and cluster headaches, according to a new research review from Australia. Migraine headaches are severely painful and usually occur with other symptoms such as nausea, vomiting and painful sensitivity to light. Cluster headaches cause sharp, burning pain on one side of the head.
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial In Patients With Migraine
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine. MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals’ proprietary Tempo(R) inhaler. In the company’s prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours.
FDA Panel Rejects Black Box Warning On Epilepsy Drugs
A panel of experts that advises the US Food and Drug Administration (FDA) voted last week to reject the Agency’s proposal to make manufacturers of 11 epilepsy drugs put the strongest level of warning label on their products (the Black Box warning). The FDA had recommended the Black Box warning because studies showed the drugs had nearly double the risk of suicide compared to placebo, although in absolute terms it was still quite small.
keep looking »